Blueprint Medicines Company Profile

What is the competitive landscape for BLUEPRINT MEDICINES

BLUEPRINT MEDICINES has one approved drug.

There are eight US patents protecting BLUEPRINT MEDICINES drugs.

There are fifty-nine patent family members on BLUEPRINT MEDICINES drugs in thirty-four countries and seventeen supplementary protection certificates in fifteen countries.

Summary for Blueprint Medicines

International Patents:	59
US Patents:	8
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Blueprint Medicines

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-005	Jun 16, 2021		RX	Yes	No	9,200,002		Y	Y
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-003	Jan 9, 2020		RX	Yes	Yes
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-005	Jun 16, 2021		RX	Yes	No
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-004	Jun 16, 2021		RX	Yes	No	11,964,980		Y	Y
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-001	Jan 9, 2020		RX	Yes	No

International Patents for Blueprint Medicines Drugs

Country	Patent Number	Estimated Expiration
Uruguay	35787
Israel	244677
Hungary	E059041
Taiwan	201546062
Hong Kong	1221461

Supplementary Protection Certificates for Blueprint Medicines Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3057969	2021/009	Ireland		PRODUCT NAME: AVAPRITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/20/1473 20200925
3057969	21C1013	France		PRODUCT NAME: AVAPRITINIB ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/20/1473 20200925; FIRST REGISTRATION: - EU/1/20/1473 20200925
3057969	PA2021003,C3057969	Lithuania		PRODUCT NAME: AVAPRITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/20/1473 20200924
3057969	122021000014	Germany		PRODUCT NAME: AVAPRITINIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/20/1473 20200924
3057969	SPC/GB21/020	United Kingdom		PRODUCT NAME: AVAPRITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK PLGB52115/0001-0003 20200925; UK EU/1/20/1473(NI) 20200925

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Blue Earth
• Blue Water Biotech
• Blueprint Medicines

Blueprint Medicines: Market Position, Strengths & Strategic Insights

Last updated: February 7, 2026

Market Position Overview

Blueprint Medicines (NASDAQ: BPMC) specializes in precision therapies targeting genetic driver mutations in cancer, rare diseases, and immune disorders. The company has established a niche with its focus on kinase inhibitors and molecular diagnostics. As of Q4 2022, Blueprint held a market cap of approximately $4 billion, with revenue primarily from its approved drugs and licensing agreements.

Key products include Ayvakit (avapritinib) and Pergyen (pralsetinib), approved for specific gastrointestinal stromal tumors (GIST) and RET fusion-positive cancers. The company's focus on personalized medicine places it among a small cohort of biotech firms with targeted therapies for rare and underserved indications.

Core Strengths

• Robust Portfolio of Targeted Therapies: Ayvakit and pralsetinib are FDA-approved, with rapidly growing indications. Ayvakit for GIST and systemic mastocytosis has demonstrated high response rates, while pralsetinib has shown efficacy in RET fusion-positive lung cancers and thyroid cancers.

• Strong R&D Pipeline: Over 20 clinical programs, including next-generation kinase inhibitors targeting resistant mutations. The pipeline emphasizes precision oncology and rare disease treatments.

• Strategic Collaborations: Licensing deals with Roche and Takeda have expanded the reach of key assets, providing revenue streams and validation.

• Regulatory Approvals and Expanding Indications: The company holds multiple approvals, supporting revenue growth. It continues to gain approvals in new indications, including systemic mastocytosis.

Market Challenges and Competitive Position

• Intense Competition in Precision Oncology: Larger companies such as Novartis, Pfizer, and AstraZeneca invest heavily in kinase inhibitors and targeted therapies, often with broader portfolios than Blueprint.

• Generic and Biosimilar Entry Risks: Patents for core products expire or face challenges, risking revenue erosion.

• Limited Commercial Scale: As a specialty biotech, Blueprint relies heavily on licensing revenue and collaborations, with less direct sales infrastructure than large pharmaceuticals.

• Pricing and Access Pressures: Healthcare policy shifts toward drug cost containment could impact pricing strategies.

Strategic Insights

• Focus on Rare and Underserved Indications: Continued advancement in orphan diseases reduces competitive pressure and enables premium pricing.

• Innovation in Next-Generation Inhibitors: Developing drugs targeting resistance mutations to extend therapeutic relevance.

• Partnership Expansion: Broaden licensing and co-development deals with larger pharma to accelerate pipeline progress and global reach.

• Investment in Diagnostics: Enhancing companion diagnostics to improve patient selection and treatment efficacy aligns with market trends toward personalized medicine.

• Geographic Expansion: Entering markets such as Europe and Asia through partnerships as regulatory pathways mature.

Competitive Landscape Comparison

Company	Market Cap (USD bn)	Focus Areas	Approved Drugs	R&D Pipeline Focus
Blueprint Medicines	4.0	Kinase inhibitors, rare diseases	Ayvakit, pralsetinib	20+ clinical programs
Novartis	210.0	Oncology, immunology, rare diseases	Multiple targeted therapies	Broad portfolio; innovative gene therapies
Pfizer	185.0	Oncology, rare diseases	Xalkori, Ibrance, Bosulif	Immuno-oncology, cell therapy
AstraZeneca	226.0	Oncology, respiratory, CV	Tagrisso, Lynparza	Next-gen kinase inhibitors, bispecifics

Regulatory and Patent Landscape

Blueprint's key assets benefit from US patents extending into the late 2020s and early 2030s. Patent cliffs pose a risk, especially as biosimilar competitors develop. The company's emphasis on rare indications offers some patent life extension through orphan drug exclusivity, which lasts seven years in the US. Efforts to secure line extensions or new formulations could prolong market exclusivity.

Financial Overview and Revenue Drivers

• Q4 2022 Revenue: Approximately $144 million, up 50% YoY.
• Main Sources: Product sales, licensing royalties, and collaboration revenues.
• Margins: Gross margin at 80%, with R&D expenses 60% of revenue, indicating high investment in pipeline development.

Key Takeaways

• Blueprint occupies a specialized segment with high unmet needs.
• The company maintains competitive advantage through its focus on genetic driver mutations, approved drugs, and strong pipeline.
• It faces significant competition from larger firms with broader therapeutic portfolios.
• Strategic expansion into new indications and regions is a primary growth driver.
• Licensing partnerships are critical for revenue and pipeline development.

FAQs

1. How does Blueprint Medicines differentiate itself from competitors? It focuses on precision kinase inhibitors for rare and underserved indications, leveraging targeted molecular diagnostics.

2. What are the primary risks for Blueprint Medicines moving forward? Patent expirations, competition from larger pharma, and pricing pressures present ongoing risks.

3. What is the company's approach to pipeline development? It advances targeted therapies in clinical stages, emphasizing resistance mutation targeting and rare diseases.

4. How important are licensing agreements in Blueprint's strategy? They significantly expand market access, generate revenue, and validate therapeutic candidates.

5. What opportunities exist in global markets? Europe and Asia represent growth avenues through partnerships, regulatory approval pathways, and unmet medical needs.

Citations

[1] Bloomberg, “Blueprint Medicines Profile,” 2023.
[2] FDA Approvals Database, 2023.
[3] Company SEC Filings, 2022.
[4] MarketWatch, “Precision Oncology Market,” 2022.